The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

FDA approves rituximab-pvvr (Ruxience®), a rituximab biosimilar, for the treatment of patients with CD20-positive NHL and CLL

Jul 25, 2019
Share:

On 23 July 2019, the US Food and Drug Administration (FDA) approved rituximab-pvvr (Ruxience®), a monoclonal antibody biosimilar to rituximab, for multiple indications in adult patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL) and chronic lymphocytic leukemia (CLL)1:

  • Monotherapy for relapsed or refractory, low-grade or follicular NHL
  • In combination with first-line chemotherapy for previously untreated follicular lymphoma and, as single-agent maintenance therapy in patients responding to a rituximab-chemotherapy combination
  • Single agent for non-progressing, low-grade NHL after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy
  • In combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens for previously untreated diffuse large B-cell lymphoma
  • In combination with fludarabine and cyclophosphamide (FC) in previously untreated and previously treated CLL

Rituximab-pvvr is the second biosimilar to rituximab that has been approved by the FDA; the first being rituximab-abbs (Truxima®) which was previously covered by the Lymphoma Hub in November 2018. Both biosimilar antibodies destroy B cells by targeting surface protein CD20.

The approval of rituximab-pvvr was based on a review of a comprehensive data package, includingthe clinical comparative study REFLECTIONS B3281006, which demonstrated the biosimilarity of rituximab-pvvr to the reference product, rituximab. The study included patients with CD20-positive, low tumor burden follicular lymphoma, and no clinically meaningful differences in safety or efficacy were found between rituximab-pvvr and the reference product.2

  1. RUXIENCE™ (rituximab-pvvr) Prescribing Information. New York. NY: Pfizer Inc: 2019. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/761103s000lbl.pdf. Accessed 23 July 2019
  2. Sharman J, et al. A Randomized, Double-Blind Efficacy and Safety Study of PF-05280586 (a Potential Rituximab Biosimilar) Compared with Rituximab Reference Product (MabThera®) in Subjects with Previously Untreated CD20-Positive, Low Tumor Burden Follicular Lymphoma (LTB-FL). Blood. 2018; 132:394
Share: